Remarkably, the majority of CP samples showed low levels of RNA editing at APOBEC3D and AZIN1 sites, while RNA editing in BC CML LSC was more variable and overall higher on average (Figure 5A,B), which was in agreement with RNA-seq and Sanger sequencing-based RNA editing analyses (Figure 1, Additional file 3: Figure S1). The gene discussed is AZIN1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.